Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pancreas cancer prevention use of polycyclic fused macrocyclic lactam compounds

A macrocyclic lactam and compound technology, applied in the field of natural medicinal chemistry, can solve the problems of non-negligible toxic effects and restricting drug efficacy, and achieve good market application and promotion prospects, high lethality, and clear activity effects

Active Publication Date: 2016-10-12
SHANGHAI JIAO TONG UNIV
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At this stage, the standard first-line drug for the treatment of pancreatic cancer is gemcitabine (gemcitabine), which is a difluoronucleoside metabolic antagonist drug that destroys cell replication, but drug resistance in the later stage severely restricts the efficacy of the drug
In addition, the combined drug regimen FOLFIRINOX, including irinotecan, oxaliplatin, 5-fluorouracil and leucovorin, has also been clinically proven to prolong the survival of patients with pancreatic cancer. However, as a camptothecin compound, irinotecan’s toxic effects cannot be ignored [X.Liu, et al., "Irinotecan Delivery by Lipid-Coated MesoporousSilica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer," ACS Nano, p .Ahead of Print,2016.]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pancreas cancer prevention use of polycyclic fused macrocyclic lactam compounds
  • Pancreas cancer prevention use of polycyclic fused macrocyclic lactam compounds
  • Pancreas cancer prevention use of polycyclic fused macrocyclic lactam compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1, Structural Identification of Polycyclic Fused Macrocyclic Lactam Compounds

[0027] Get S.xiamenensis M6 bacterial strain (being Streptomyces xiamenensis (Streptomyces xiamenensis) CGMCC No.4.3534 and carry out liquid fermentation culture (30 liters), 7 days, supernatant after centrifugation is extracted 3 times with ethyl acetate. The extracts are combined, concentrated , to get 3 grams of total extract.Get the total extract and add 9 grams of reverse phase mixing samples after dissolving with an appropriate amount of chloroform-methanol mixed solvent, go up to the normal phase silica gel glass decompression column that is packed with 50 grams, wash with methanol-water gradient The removal is specifically: 50%, 80%, 100% methanol-water gradient elution, each gradient elution volume is 200mL, 150-100ml / bottle is received, and the polarity of the elution solvent is adjusted by increasing the amount of methanol in chloroform Gradient increases, and each eluti...

Embodiment 2

[0035] Example 2. Polycyclic fused macrocyclic lactam compounds inhibit the proliferation and viability of human pancreatic cancer cells

[0036] The materials are as follows:

[0037] Cells: human pancreatic cancer cells PANC-1, BxCP1; drug: compound 1 obtained from the above examples. Among them, compound 1 was used as the drug-treated experimental group, and compound 2 was used as the drug-treated comparison group.

[0038] Method: PANC-1, BxCP1 cells were seeded in 96-well plate, 0.5×10 per well 3 cells. After 24 hours, the liquid was changed and drugs were added, the control group was DMSO, and the final concentration was 1 / 1000. Cell viability was measured 0, 1, 2, 3, 4, 5, and 6 days after adding the drug. The measurement method is aspirating out the medium, adding 100 μl of complete medium and 10 μl of CCK-8 reagent to each well, and incubating in the incubator for 60 minutes to measure the light absorption value with a microplate reader at a wavelength of 450 nm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pancreas cancer prevention use of polycyclic fused macrocyclic lactam compounds. The structural formula of the polycyclic fused macrocyclic lactam compounds is shown in the description; and in the formula, R1 is OCH3 or H, R2 is Cl or OH, and R3 is OCH3 or H. The polycyclic fused macrocyclic lactam compounds are separated through separating and purifying a fermentation liquid of Streptomyces xiamenensis CGMCC No.4.3534 from mangrove soil. Prepared ikarugamycin and derivatives thereof can inhibit proliferation and vitality of human pancreas cancer cells, and can be used to prepare pancreas cancer prevention drugs.

Description

technical field [0001] The invention belongs to the field of natural medicinal chemistry, and in particular relates to the anti-pancreatic cancer application of a class of polycyclic tetramate macrolactam (polycyclic tetramate macrolactam, hereinafter referred to as PTM). Background technique [0002] Pancreatic ductal adenocarcinoma (Pancreatic ductal adenocarcinoma, PDAC, hereinafter referred to as pancreatic cancer) is one of the common malignant tumors of the digestive system, the mortality rate is close to the incidence rate, and the 5-year overall survival rate is less than 6% [T.Seufferlein and J.Mayerle, "Pancreatic cancer in 2015Precision medicine inpancreatic cancer-fact or fiction?," Nat.Rev.Gastroenterol.Hepatol.,vol.13,pp.74-75,2016.]. In recent years, its morbidity and mortality have been increasing worldwide, and it has become one of the malignant tumors with the worst prognosis[J.D.Byrne, et al., "Iontophoretic device delivery for the localized treatment of p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D487/08C07D491/18C12P17/18A61K31/407A61P35/00
CPCC07D487/08C07D491/18C12P17/18C12P17/182
Inventor 徐岷涓张志刚徐俊杨小妹何昆燕余河霖蒋书恒
Owner SHANGHAI JIAO TONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com